A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Ribociclib (Primary)
Indications Colorectal cancer; Malignant melanoma; Skin cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Array BioPharma; Novartis; Novartis Farma; Pfizer

14 Jun 2023 This trial has been completed in Italy, according to European Clinical Trials Database record.
24 May 2023 This trial has been completed in Belgium (End Date: 09 Mar 2023), according to European Clinical Trials Database record.
22 Nov 2022 Planned End Date changed from 29 Dec 2022 to 2 Mar 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com